SGR-2921
A First-In-Human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy In Subjects With Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 50 patients (estimated)
- Sponsors
- Schrödinger, Inc.
- Tags
- CDC7 Inhibitor
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1784
- NCT Identifier
- NCT05961839
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.